Regeneron Pharmaceuticals and Telix Pharmaceuticals have entered into a strategic partnership to co-develop and commercialise next-generation radiopharmaceuticals for the treatment of solid tumours. Under the agreement, Telix will receive an upfront payment of USD 40 million to support four initial programs, with Regeneron holding an option to expand the collaboration to an additional four projects. The companies will share global development costs and commercial profits equally, with Telix retaining co-promotion rights for certain products. Should Telix opt out of co-funding a specific program, that project would be eligible for up to USD 535 million in milestone payments and low double-digit royalties on net sales.

The collaboration combines Telix's radiopharmaceutical development platform and manufacturing infrastructure with Regeneron's expertise in antibody discovery, including its VelocImmune platform, to target multiple solid tumour antigens. The partnership also includes plans to develop diagnostic radiopharmaceuticals to support patient selection and treatment monitoring, aligning with a shared commitment to precision oncology.

PharmCube's NextBiopharm® database shows that Telix holds the 13th-largest radioligand therapy portfolio in the industry. Click here to request a free trial for NextBiopharm®.